Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
Open Access
- 28 April 2023
- journal article
- research article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-15
Abstract
Myeloid-derived suppressor cells (MDSCs) were found to gradually accumulate in the orthotopic esophageal cancer mouse model during tumor progression. Although the roles of MDSCs in promoting tumor growth and inhibiting immune response have been extensively explored, currently, there are still no effective means for targeting MDSCs clinically. The deficiency of specific markers of MDSCs was responsible for the limited strategy to eliminating in clinic. This study identified that GPR84 was exclusively overexpressed on MDSCs. It was further found that GPR84 was prominently expressed on MDSCs in clinical samples and tumor mouse models, which drives the immunosuppression on CD8+T cells by inhibiting PD-L1 degradation in lysosomes. Furthermore, G-CSF and GM-CSF were found to induce GPR84 expression through the STAT3/C/EBPβ signaling pathway. In addition, GPR84+MDSCs and PD-L1+MDSCs were highly accumulated in anti-PD-1 therapy-resistant patients with esophageal cancer, and high GPR84 signature risk was verified as a negative factor for the overall survival of patients with anti-PD-1 treatment. Finally, GPR84 antagonism combined with an anti-PD-1 antibody enhanced the antitumor responses. Therefore, targeting GPR84 enhanced anti-PD-1 efficacy in esophageal cancer and other malignant tumors. This combination therapy has the potential for tumor therapy in clinics.Keywords
Funding Information
- National Natural Science Foundation of China (U1804281, 91942314)
- Technological projects in Henan Province
This publication has 29 references indexed in Scilit:
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedJournal of Clinical Investigation, 2015
- GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s diseaseBrain, Behavior, and Immunity, 2015
- GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesisBlood, 2014
- Langerhans cell histiocytosis with atypical histiocytic marrow infiltrationBlood, 2014
- Medium-chain Fatty Acid-sensing Receptor, GPR84, Is a Proinflammatory ReceptorJournal of Biological Chemistry, 2013
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription FactorImmunity, 2010
- Medium-chain Fatty Acids as Ligands for Orphan G Protein-coupled Receptor GPR84Journal of Biological Chemistry, 2006
- Reducing the Immune Response to ImmunotoxinClinical Cancer Research, 2004
- Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated MiceClinical Cancer Research, 2004